Infectious Disease Special Edition news story
The novel antiretroviral combination regimen bictegravir-lenacapavir (BIC/LEN; Bixlenvo, Gilead Sciences) maintains high viral suppression rates, even in the presence of preexisting resistance-associated mutations, according to the findings of the phase 3 ARTISTRY-2 trial, which were presented during the HIV Glasgow 2026 (abstract 048).
The trial, which was designed to evaluate the efficacy and safety of switching to the BIC/LEN single-tablet regimen compared with continuing bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) in 574 participants with HIV, found that the presence of baseline resistance-associated mutations did not affect the efficacy of either regimen during 48 weeks of treatment (P>0.05). Treatment-emergent resistance-associated mutations were rare, occurring in one of the 383 participants who received BIC/LEN; phenotypic susceptibility to the study drugs was maintained.
Read the full news story here.
/free registration is required/
View all Infectious Disease Special Edition reports from HIV Glasgow 2026
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.